• Cryptomonnaies
  • Marchés de Prédiction
  • Actualités
  • Trading Agentique
  • Articles
  • Ligues

Rechercher des Cryptomonnaies

Cryptomonnaies en tendance

CoinRithm

Entreprise

Entité légale
Bees-x Limited
Numéro de société
13308136
Constituée en
England and Wales
Siège social
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm est un service d'information et de recherche exploité par Bees-x Limited. Il n'est pas autorisé par la Financial Conduct Authority (FCA) à exercer des activités réglementées, et rien sur ce site ne constitue un conseil financier.

Explorer

CryptomonnaiesMarchés de PrédictionActualitésArticlesAgent ArenaLigues

Fonctionnalités

Tableau de bordÉchange FictifTrading AgentiquePortefeuilleListe de suiviParamètres

Entreprise

À Propos de NousMethodologieConditions d'utilisationPolitique de ConfidentialitéPolitique en Matière de CookiesAvertissement

Support

Contactez le SupportFAQKit développeurDocs MCP

Réseaux

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Tous droits réservés.
Disponible sur Google PlayTélécharger sur l'App Store
  • Accueil
  • MarchésMarchés de Prédiction
  • Actualités
  • Tableau de bord
  1. Marchés de Prédiction
  2. Health & Medicine
  3. FDA approves Daraxonrasib this year?
FDA approves Daraxonrasib this year?

FDA approves Daraxonrasib this year?

0.5% (24h)Health & MedicineOne-Off6mo
PolymarketPolymarketVérifier la disponibilitéSans KYC2% de frais
Probabilité implicite actuelle
Oui
Oui 71%+0.0%
Qualite du marche

24 / 100

Faible qualité
Volume 24h

0 €

Liquidité

1,6 k €

Faible liquidité
Achat / Vente

67.0% / 75.0%

Spread

11.9%

Spread large
Variation 7j

+3.0%

Données du marché

Mis à jour il y a 5 minutes

13 mai 26, 21:5431 déc. 26, 0:00

Tendances

Résultat24hProbabilité

Résultat choisi

Yes71%

Règles

Daraxonrasib is an RAS inhibitor drug developed by Revolution Medicines and currently in trial to treat RAS-mutated cancers.

Polymarket
  • This market will resolve to "Yes" if the U.S.
  • Food and Drug Administration (FDA) grants a full or conditional approval for a drug product whose active ingredient is Revolution Medicines’ daraxonrasib (including any brand name or identifier) for any use between market creation and December 31, 2026, 11:59 PM ET.
  • Otherwise, this market will resolve to "No."
  • An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
  • The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

Marchés Associés

Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

145,3 k €
Oui: 5%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

16,6 k €
Oui: 10%PolymarketPOLYMARKET
Ebola pandemic in 2026?

Ebola pandemic in 2026?

8,7 k €
Oui: 8%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

1,3 k €
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Which disease will be eradicated next in humans?

462,5 €
Polio: 26.7%Manifold MarketsMANIFOLD MARKETS
When, where or how will Trump die?

When, where or how will Trump die?

137,8 €
2025: 0%Manifold MarketsMANIFOLD MARKETS

Actifs dans ces sujets

BitcoinBTC$62,853.43+2.49%EthereumETH$1,658.07+1.88%SolanaSOL$65.29+1.88%DogecoinDOGE$0.0849+1.67%XRPXRP$1.12+0.68%BNBBNB$596.70+1.82%

Actualités Associées

Chainalysis reveals $100 million peptide market built on cryptoCrypto NewsGray peptide vendors embrace stablecoins as safety fears deepenCrypto NewsOpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.NewsBrian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto News

Règles

Daraxonrasib is an RAS inhibitor drug developed by Revolution Medicines and currently in trial to treat RAS-mutated cancers.

Polymarket
  • This market will resolve to "Yes" if the U.S.
  • Food and Drug Administration (FDA) grants a full or conditional approval for a drug product whose active ingredient is Revolution Medicines’ daraxonrasib (including any brand name or identifier) for any use between market creation and December 31, 2026, 11:59 PM ET.
  • Otherwise, this market will resolve to "No."
  • An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
  • The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs